CT引导放射性125I粒子植入治疗23例浅表淋巴结转移瘤

doi:10.6040/j.issn.1671-7554.0.2016.1350

摘要/Abstract

摘要： 目的探讨放射性¹²⁵I粒子植入治疗浅表淋巴结转移瘤的技术方法、近期疗效及临床意义。方法对2014年12月至2016年6月放射性¹²⁵I粒子植入治疗的23例浅表淋巴结转移瘤的患者进行回顾性分析。所有患者术前应用治疗计划系统(TPS)制定植入计划,根据术前计划在CT引导下行浅表淋巴结转移瘤¹²⁵I粒子植入术,术后行质量验证。分别于术后1、3、6、9、12个月复查CT,进行临床疗效及并发症评估。结果对23例患者、28个靶区病灶进行了治疗,术后1、3、6、9、12个月的局部控制率分别为84.6%、82.4%、81.2%、83.3%和85.7%。中位随访时间为9个月( 1~16个月),生存15例,死亡8例。靶区病灶的中位局部控制时间为12个月(95% CI: 7.4, 16.5),而中位无进展生存时间为3个月(95% CI: 0.3, 5.7),P=0.194。术后出现急性皮肤放疗反应Ⅰ/Ⅱ级6例,无其他并发症和不良反应。结论 ¹²⁵I粒子植入治疗浅表淋巴结转移瘤,方法可行,近期疗效可靠,安全性较高,是局部治疗有效方法之一。

关键词: 浅表淋巴结转移瘤, 局部控制率, ¹²⁵I粒子, 并发症

Abstract: Objective To evaluate the efficacy and complications of CT-guided permanent ¹²⁵I seed brachytherapy in patients with the superficial lymph node metastases. Methods Clinical data of 23 patients with 28 superficial lymph node metastases who underwent CT-guided ¹²⁵I seed brachytherapy during Dec. 2014 and Jun. 2016 were retrospectively reviewed. Brachytherapy was preplanned for all patients using a 3-dimensional radiation therapy planning system. With CT guidance, ¹²⁵I seed was placed into the metastases. Dosimetry verification was performed immediately after operation. Efficacy and complications were evaluated 1, 3, 6, 9 and 12 months postoperatively. Results The median local control rate of 1, 3, 6, 9 and 12 months was 84.6%, 82.4%, 81.2%, 83.3% and 85.7%, respectively. The median follow-up was 9 months(1-16 months), during which 8 patients died and 15 survived. The local control time was 12 months(95% CI: 7.4, 16.5), the median progression-free-survival(PFS)was 3 months(95% CI: 0.3, 5.7), P=0.194. No major complications occurred during or after brachytherapy except for Ⅰ/Ⅱ acute skin radioreaction in 6 cases. Conclusion CT-guided ¹²⁵I seed brachytherapy is a safe and effective treatment for superficial lymph node metastases with few complications.

Key words: Complications, Local control rate, Superficial lymph node metastases, ¹²⁵I seed

中图分类号:

R730.5

林琦,张颖,戴建建,徐瑞彩,杨琦,耿宝成,韩明勇. CT引导放射性¹²⁵I粒子植入治疗23例浅表淋巴结转移瘤[J]. 山东大学学报（医学版）, 2017, 55(2): 38-44.

LIN Qi, ZHANG Ying, DAI Jianjian, XU Ruicai, YANG Qi, GENG Baocheng, HAN Mingyong. CT-guided ¹²⁵I seed brachytherapy for superficial lymph node metastases: a report of 23 cases[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 38-44.

参考文献

[1] 汤钊猷. 现代肿瘤学[M]. 上海: 上海医科大学出版社, 1993: 102.
[2] 谷铣之, 殷蔚伯, 刘泰福, 等. 肿瘤放射治疗学[M]. 北京: 北京医科大学、中国协和医科大学联合出版社, 1991: 143.
[3] 王俊杰, 修典荣, 冉维强. 放射性粒子组织间近距离治疗肿瘤[M]. 北京: 北京大学医学出版社, 2014: 162-174.
[4] Huo X, Wang H, Yang J, et al. Effectiveness and safety of CT-guided ¹²⁵I seed brachytherapy for postoperative locoregional recurrence in patients with none-small cell lung cancer[J]. Brachytherapy, 2016, 15(3): 370-380.
[5] 房菲菲, 张颖, 林琦, 等. CT引导放射性¹²⁵I粒子植入治疗转移性肝癌的临床疗效[J]. 山东大学学报(医学版), 2016, 54. doi:10.6040/j.issn.16717554.0.2016.1106. FANG Feifei, ZHANG Ying, LIN Qi, et al. Clinical efficacy of CT guided ¹²⁵I seed brachytherapy in the treatment of metastatic hepatic carcinoma[J]. Journal of Shandong University(Health Sciences), 2016, 54. doi:10.6040/j.issn.16717554.0.2016.1106.
[6] Lin L, Wang J, Jiang Y, et al. Interstitial ¹²⁵I seed implantation for cervical lymph node recurrence after multimodal treatment of thoracic esophageal squamous cell carcinoma[J]. Technol Cancer Res Treat, 2015, 14(2): 201-207.
[7] Gao F, Li C, Gu Y, et al. CT-guided ¹²⁵I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients[J]. Eur J Radiol, 2013, 82(2): 70-75.
[8] 高飞, 顾仰葵, 黄金华, 等. CT引导下¹²⁵Ⅰ近距离治疗肝癌腹膜后转移性淋巴结的临床价值[J]. 中华医学杂志, 2013, 93(27): 2155-2157. GAO Fei, GU Yangkui, HUANG Jinhua, et al. Clinical value of CT-guided ¹²⁵I brachytherapy for retroperitoneal metastatic lymph node from PHC[J]. National Medical Journal of China, 2013, 93(27): 2155-2157.
[9] 蒲德利, 廖江荣, 彭刚. 放射性¹²⁵I粒子植入近距离放射治疗18例口腔癌的疗效观察[J]. 介入放射学杂志, 2013, 22: 851-853. PU Deli, LIAO Jiangrong, PENG Gang. The therapeutic effect of brachytherapy with¹²⁵I seed implantation for oral cancer: observation of 18 cases[J]. J Intervent Radiol, 2013, 22: 851-853.
[10] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline(version1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
[11] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group(RTOG)and the european organization for research and treatment of cancer(EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5): 1341-1346.
[12] Yao L, Jiang Y, Jiang P, et al. CT-guided permanent ¹²⁵I seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy[J]. Brachytherapy, 2015, 14(5): 662-669.
[13] 柴树德, 郑广钧. 胸部肿瘤放射性粒子治疗学[M]. 北京: 人民卫生出版社, 2012: 17-29.
[14] Zhang T, Lu M, Peng S, et al. CT-guided implantation of radioactive ¹²⁵I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy[J]. J Cancer Res Clin Oncol, 2014, 140(8): 1383-1390.
[15] Li J, Xie Q, Wang W, et al. CT-guided implantation of ¹²⁵I seeds(permanent brachytherapy)for metastatic tumors of the hepatic portal system: effectiveness and safety in 13 patients[J]. Brachytherapy, 2016, 15(2): 224-230.
[16] Li W, Guan J, Yang L, et al. Iodine-125 brachytherapy improved overall survival of patients with inoperable stage Ⅲ/Ⅳ non-small cell lung cancer versus the conventional radiotherapy[J]. Med Oncol, 2015, 32(1): 395. doi: 10.1007/s12032-014-0395-8.
[17] Aronowitz JN.Introduction of transperineal image-guided prostate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2014, 89(4): 907-915.
[18] Zuber S, Wei S, Baaske D, et al. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review[J]. Radiat Oncol, 2015, 10: 49. doi: 10.1186/s13014-015-0349-0.
[19] Zhang L, Lu J, Wang Z, et al. Clinical efficacy of computed tomography-guided iodine-125 seed implantation therapy in patients with advanced spinal metastatic tumors[J]. Onco Targets Ther, 2015, 9: 7-12. doi: 10.2147/OTT.S95410.
[20] Zhang L, Chen LH, Wang J, et al. CT-guided radioactive ¹²⁵I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma[J]. Clin Radiol, 2014, 69(6): 624-629.
[21] Xiang Z, Mo Z, Li G, et al. ¹²⁵I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments[J]. Oncotarget, 2016, 7(14): 18384-18393.
[22] Gobardhan PD, de Wall LL, van der Laan L, et al. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy[J]. Ann Oncol, 2013, 24(3): 668-673.
[23] 张忠涛, 隋庆兰. 吴善良, 等. CT导引植入¹²⁵I放射性粒子治疗颈部淋巴结转移癌的临床应用[J]. 介入放射学杂志, 2015, 24(10): 881-884. ZHANG Zhongtao, SUI Qinglan, WU Shanliang, et al. Clinical application of CT-guided ¹²⁵I radioactive seed implantation in treating cervical lymph node metastasis[J]. J Intervent Radiol, 2015, 24(10): 881-884.
[24] 王娟, 孙美玲, 张宏涛, 等. 外放疗后复发颈部淋巴结转移癌17例¹²⁵I粒子植入治疗的初步疗效[J]. 介入放射学杂志, 2014, 23(9): 784-787. WANG Juan, SUN Meiling, ZHANG Hongtao, et al. Radioactive ¹²⁵I seed implantation for the treatment of recurrent cervical lymphatic metastases after radiotherapy: preliminary results in 17 cases[J]. J Intervent Radiol, 2014, 23(9): 784-787.
[25] 张颖, 林琦, 袁苑, 等. 3D打印个体化模板联合CT引导¹²⁵I粒子植入治疗恶性肿瘤质量评价[J]. 山东大学学报(医学版), 2016, 54(11): 44-50. ZHANG Ying, LIN Qi, YUAN Yuan, et al. The feasibility of 3D print individual template combined with CT guided ¹²⁵I seed implantation for malignant tumor[J]. Journal of Shandong University(Health Sciences), 2016, 54(11): 44-50.
[26] 张颖, 林琦, 韩明勇, 等. 3D打印个体化模板联合CT引导治疗胸壁肿瘤1例[J]. 山东大学学报(医学版), 2016, 54(4): 94-96.
[27] 王俊杰. 3D打印技术与精准粒子植入治疗学[M]. 北京: 北京大学医学出版社, 2016: 54-63.
[28] 江萍, 马月, 王俊杰, 等. 超声引导放射性¹²⁵I粒子植入治疗头颈部复发肿瘤[J]. 北京大学学报(医学版), 2012, 44(2): 291-294. JIANG Ping, MA Yue, WANG Junjie, et al. Ultrasound guided implantation of radioactive 125I seeds for treatment of recurrent head and neck carcinomas[J]. Journal of Peking University(Health Sciences), 2012, 44(2): 291-294.

相关文章 15

[1]	董恣豪,刘喆,王浩,于辰曦,杨光,丰浩田. 髋关节镜下关节囊不同切开方式早期术后并发症[J]. 山东大学学报 (医学版), 2026, 64(5): 83-87.
[2]	史潇兮,辛世杰. 腹主动脉瘤的开放手术[J]. 山东大学学报 (医学版), 2024, 62(9): 26-29.
[3]	王瑞霞,苏童,赵淑磊. 内镜逆行性胆胰管造影术罕见并发症-胆道支架无法拔除1例[J]. 山东大学学报 (医学版), 2024, 62(2): 113-115.
[4]	李红梅,蔡敏,周立,姚欣雨,刘力. 不同膈肌超声功能指标在腹部手术后肺部并发症中的预测价值[J]. 山东大学学报 (医学版), 2024, 62(10): 115-124.
[5]	徐荣坤,王连雷,原所茂,田永昊,刘新宇. 腰椎术中腹主动脉损伤1例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(6): 121-124.
[6]	穆彦熹,李金洲,陈康,梁红英,姚亚龙,汪文杰,陈晓. 443例胃癌根治术后发生肺部并发症的危险因素[J]. 山东大学学报 (医学版), 2023, 61(4): 37-41.
[7]	王艳莉,冯晔,周秀耕,杨跃,吴楠,方玉,阎石,李少雷,吕超,韩超,杜松涛. 33例食管癌患者围术期补充乳清蛋白粉对术后并发症的预防作用[J]. 山东大学学报 (医学版), 2022, 60(3): 64-70.
[8]	林均馨,刘玉江,刘培来,万连平,张鹏,杜建春,刘泽淼,孔杰,高升焘. 固定平台单髁术后胫骨假体周围骨折2例[J]. 山东大学学报 (医学版), 2022, 60(3): 96-99.
[9]	张建平,罗莺儿. 抗凝药物在反复不良妊娠治疗中的应用进展[J]. 山东大学学报 (医学版), 2021, 59(8): 14-19.
[10]	邹俊逸,张辉,张歆杰,李子佳,许明雷,王东. 110例原位心脏移植临床经验[J]. 山东大学学报 (医学版), 2021, 59(8): 86-91.
[11]	罗应舒,李宾,许昌芹,姜军梅,许洪伟. 240例上消化道黏膜下肿瘤内镜治疗的疗效及并发症评估[J]. 山东大学学报 (医学版), 2021, 59(3): 74-80.
[12]	郭志华,赵大庆,邢园,王薇,梁乐平,杨静,赵倩倩. Ⅰ期端端吻合术治疗重度颈段气管狭窄临床分析[J]. 山东大学学报 (医学版), 2020, 1(7): 72-76.
[13]	程瑞林,黄政,李正勋,张宁,胡勇,徐文鹏. 小切口腓肠肌腱翻瓣术治疗5例陈旧性跟腱断裂[J]. 山东大学学报 (医学版), 2020, 58(6): 92-96.
[14]	吴成威,孙博实,周军德,蒋天明,迟强. 术前口服多糖溶液对结直肠癌患者术后胰岛素抵抗的关联性研究[J]. 山东大学学报 (医学版), 2019, 57(9): 48-53.
[15]	王冰. 腰椎完全内镜经椎板间入路技术的临床教程[J]. 山东大学学报 (医学版), 2019, 57(5): 23-29.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

CT引导放射性¹²⁵I粒子植入治疗23例浅表淋巴结转移瘤

CT-guided ¹²⁵I seed brachytherapy for superficial lymph node metastases: a report of 23 cases

PDF (PC)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

多维度评价

本文评价

推荐阅读 0